Biocryst Pharmaceuticals reported $511.71M in Current Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
DBV Technologies DBVT:US USD 225.7M 34.26M
Alnylam Pharmaceuticals ALNY:US USD 2.69B 219.21M
Chugai Pharma 4519:JP JPY 1.34T 151.97B
Daiichi Sankyo 4568:JP JPY 1.44T 19.68B
Enanta Pharmaceuticals ENTA:US USD 311.71M 1.32M
Gilead Sciences GILD:US USD 15.23B 1.67B
GlaxoSmithKline GSK:LN GBP 20.77B 520M
Glaxosmithkline GSK:US GBP 20.77B 520M
Intra Cellular Therapies ITCI:US USD 759.76M 29.45M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Mirati Therapeutics MRTX:US USD 1.23B 22.86M
Neurocrine Biosciences NBIX:US USD 1.21B 186.2M
Novavax NVAX:US USD 1.76B 376.04M
Ptc Therapeutics PTCT:US USD 517.26M 177.41M
Regeneron Pharmaceuticals REGN:US USD 15.43B 101.3M
Roche Holding ROG:VX 30.32B 5.31B
Sarepta Therapeutics SRPT:US USD 2.63B 156.63M
Ultragenyx Pharmaceutical RARE:US USD 1.01B 334.13M
Vertex Pharmaceuticals VRTX:US USD 12.27B 767.5M
YTE INCY:US USD 3.82B 195.27M